1 Ocak 2017 Dergi makalesi Açık Erişim

Erturk, Zeliha; Buber, Esra; Ozen, Haluk; Celikbicak, Omur; Salih, Bekir; Acan, N. Leyla

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/47033</identifier>
  <creators>
    <creator>
      <creatorName>Erturk, Zeliha</creatorName>
      <givenName>Zeliha</givenName>
      <familyName>Erturk</familyName>
      <affiliation>Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Buber, Esra</creatorName>
      <givenName>Esra</givenName>
      <familyName>Buber</familyName>
      <affiliation>Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Ozen, Haluk</creatorName>
      <givenName>Haluk</givenName>
      <familyName>Ozen</familyName>
      <affiliation>Hacettepe Univ, Fac Med, Dept Urol, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Celikbicak, Omur</creatorName>
      <givenName>Omur</givenName>
      <familyName>Celikbicak</familyName>
      <affiliation>Hacettepe Univ, Fac Sci, Dept Chem, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Salih, Bekir</creatorName>
      <givenName>Bekir</givenName>
      <familyName>Salih</familyName>
      <affiliation>Hacettepe Univ, Fac Sci, Dept Chem, Ankara, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Acan, N. Leyla</creatorName>
      <givenName>N. Leyla</givenName>
      <familyName>Acan</familyName>
      <affiliation>Hacettepe Univ, Fac Med, Dept Med Biochem, Ankara, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Mycobacterium Brumae Extract Fractions With Potential Immunotherapeutic Activity For Bladder Cancer</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2017</publicationYear>
  <dates>
    <date dateType="Issued">2017-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/47033</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.4274/uob.905</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Objective: Immunotherapy with intravesical Bacillus Calmette-Guerin (BCG) application is a gold standard treatment for high risk non-muscle invasive bladder cancer (NMIBC), despite its local and systemic side effects. We aimed to develop less toxic and more powerful therapeutic agents for the treatment of bladder cancer than live strain.</description>
  </descriptions>
</resource>